flutiform is the first pressurised metered-dose inhaler to combine the ICS, fluticasone propionate, with the fast-acting inhaled LABA, formoterol. 2 flutiform is licensed for asthma maintenance ...

U.K.-based SkyePharma's Flutiform, an inhaled combination of fluticasone and formoterol, has been launched in Germany by the company's partner, Mundipharma, as an asthma maintenance therapy.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma. Napp Pharmaceuticals says the UK is ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...

Mundipharma today announced new data from four studies demonstrating efficient drug delivery characteristics with flutiform ® k-haler ®, a novel, breath-triggered inhaler, currently in development.

There was good news for Cambridge, UK-based Napp Pharmaceuticals this week as cost regulators in Scotland approved the use of its asthma inhaler Flutiform for National Health Service use. There was ...

LONDON (MarketWatch) -- U.K. drug delivery company SkyePharma PLC Tuesday said it has signed a deal with Kyorin Co. Ltd. (4569.TO) to develop and distribute its key experimental product, asthma ...

It's likely that SkyePharma isn't having a "Happy New Year" just yet. That's because the British drug delivery company now stands to face an additional delay of between 6 and 9 months in the approval ...

Rapid changes in the way new drugs are developed and brought to market has put a premium on finding the right partners for success. The breakdown of the old big pharma model which did everything from ...

Cambridge, UK, 16 April 2024 – Mundipharma and Vectura will now progress development of the reformulation of flutiform ® (fluticasone propionate/formoterol fumarate) following long-term collaboration, ...

- flutiform k-haler achieved high levels of lung deposition of over 44% of delivered dose - Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via ...